Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
Cancers|November 13, 2025
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?Sonia Morè, Massimo Offidani, Laura Corvatta, et al.Cancers|February 13, 2025
Long-Term Survival with Multiple Myeloma: An Italian ExperienceFrancesca Fazio, Martina Gherardini, Elena Rossi, et al.The Lancet. Haematology|August 6, 2025
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trialSara Bringhen, Lorenzo Cani, Elisabetta Antonioli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple MyelomaLuca Bertamini, Stefania Oliva, Delia Rota-Scalabrini, et al.Leukemia|May 24, 2022
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosisAlice Nevone, Maria Girelli, Silvia Mangiacavalli, et al.Clinical Lymphoma, Myeloma & Leukemia|October 1, 2025
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma PatientsSonia Morè, Massimo Offidani, Laura Corvatta, et al.Frontiers in Oncology|April 4, 2022
Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE PlatformFabio Efficace, Andrea Patriarca, Mario Luppi, et al.Haematologica|March 19, 2026
A nationwide Italian GIMEMA survey on tandem autologous stem cell transplantation for newly diagnosed multiple myeloma patients treated with daratumumab, bortezomib, thalidomide and dexamethasoneCarmine Liberatore, Alfonso Piciocchi, Donatella Vincelli, et al.Haematologica|March 26, 2026
Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experienceCarmine Liberatore, Virginia Valeria Ferretti, Paola Tacchetti, et al.Annals of Hematology|October 7, 2025
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) ItalyConcetta Conticello, Vittorio Del Fabro, Alessandra Romano, et al.Pageof 5